Ingredients
Stannous fluoride and gum health
Stannous fluoride really does reduce gum inflammation, and it is not the fluoride doing it. The active part is the tin. That one fact explains the benefits, the staining and the rare reactions all at once.
There are two different fluorides on the shelf
Most toothpaste uses sodium fluoride. Sodium is inert here. It is just the thing the fluoride is attached to, and it does nothing once the two separate in your mouth.
Stannous fluoride attaches the fluoride to tin instead, and tin is not inert at all. You are getting two active ingredients in one, and they do different jobs. The fluoride handles cavities. The tin handles gums, sensitivity, and a few other things you may not have asked for.
How the tin calms gums down
Bleeding gums are not really damage from bacteria. They are your own immune system responding to bacteria sitting along the gumline. Turn down the signal and the inflammation settles.
Certain bacteria carry a molecule called lipopolysaccharide in their outer wall. Your immune system is built to detect exactly that molecule, and detecting it is what starts the inflammation. Tin binds to it directly, so less of it gets recognized and less inflammation follows.
Tin also attacks the bacteria themselves, gathering between the layers of their outer membrane until it ruptures. Notably, zinc and triclosan, the other common antibacterials in toothpaste, do not bind that molecule. This part is specific to tin.
How well does it actually work?
Well, and the effect is not subtle. Pooling 18 randomized trials covering 2,890 people, stannous fluoride toothpaste produced around 51 percent fewer bleeding sites than a control toothpaste over three months or less.
Halving bleeding sites is a large effect for a toothpaste. If you have bleeding gums, this is one of the few things on a supermarket shelf with real evidence behind it.
What the FDA has and has not done
The label claims are real. American stannous fluoride toothpastes carry FDA-recognized wording like "helps prevent gingivitis" and "helps interfere with the harmful effects of plaque associated with gingivitis."
Two honest footnotes. The rulebook those claims sit under was proposed in 2003 and has still never been finalized, so it remains a tentative monograph rather than settled regulation. And when the evidence was reviewed, the data on reducing plaque specifically was judged inconclusive. That is why the permitted claim is carefully worded around gingivitis rather than around plaque.
The trade-offs come from the same tin
Tin oxidizes in your mouth. That reaction is useful for sensitive teeth, because the tin compounds it forms plug the microscopic open tubes in exposed roots. It is less useful on the visible surface, where the same chemistry causes the brown staining stannous toothpastes are known for. Modern formulations are stabilized to limit this, not to eliminate it.
And the rare irritation reports point the same way. In the one published case where allergy testing found a culprit, it was the tin, not the fluoride. Same element behind the benefit and behind the occasional problem.
The short version
- Stannous fluoride is a genuinely different product from ordinary sodium fluoride toothpaste.
- It has good evidence for bleeding gums, roughly halving bleeding sites in pooled trials.
- The tin does that work, along with helping sensitivity, staining, and the rare reaction.
- It is not a treatment for established gum disease. Gingivitis is reversible inflammation; periodontitis involves bone loss and needs a dentist.
Read the full evidence review The tin chemistry, the LPS mechanism, the pooled trial data, and why the FDA monograph behind the claim was never finalized.
Stannous fluoride is treated in consumer coverage as a variant of fluoride toothpaste. It is better understood as two actives in one salt. The fluoride ion does what fluoride does, described in how fluoride works. The stannous ion, Sn(II), is a broad-spectrum antimicrobial with a specific affinity for bacterial lipopolysaccharide, and it is responsible for the anti-gingivitis effect, the anti-sensitivity effect, the staining, and probably the rare contact reactions. Almost everything distinctive about this ingredient is the tin.
Key points
- The stannous ion binds lipopolysaccharide in gram-negative bacterial cell walls, suppressing Toll-like receptor activation and the inflammatory cascade it triggers. Zinc and triclosan do not share this affinity.
- A meta-analysis of 18 randomized gingivitis trials in 2,890 subjects reported a mean 51 percent reduction in bleeding sites versus a negative control dentifrice at three months or less.
- Sn(II) oxidizes to Sn(IV) and hydrolyzes to insoluble tin compounds that occlude exposed dentin tubules, which is the anti-sensitivity mechanism.
- The same oxidation chemistry produces tin oxide, which is abrasive and stains. This is a formulation problem managed by stabilization rather than eliminated.
- US label claims for gingivitis rest on a monograph proposed in 2003 that was never finalized, and the plaque-reduction data specifically was judged inconclusive.
Two actives in one salt
In sodium fluoride the counter-ion is doing nothing of interest. Sodium dissociates and is biologically irrelevant at these quantities; the dentifrice is a fluoride delivery vehicle and nothing else.
Stannous fluoride is not that. Tin(II) is redox-active, binds avidly to several biological targets, and has antimicrobial activity independent of fluoride. Reviews attribute stannous fluoride's superior clinical performance over sodium fluoride and sodium monofluorophosphate to the tin(II) species rather than to fluoride alone.1 The practical consequence is that swapping between the two salts is not a like-for-like substitution.
The anti-gingivitis mechanism
Gingivitis is a host inflammatory response to the biofilm at the gingival margin rather than direct bacterial destruction of tissue. The clinically useful intervention is therefore either to reduce the biofilm or to reduce the host response to it. Stannous fluoride appears to do both.
The specific mechanism is the interesting one. Stannous ions have a pronounced binding affinity for lipopolysaccharide, the outer-membrane component of gram-negative bacteria and the canonical ligand for Toll-like receptor 4. Binding LPS suppresses the receptor activation that initiates and sustains gingival inflammation.2 This affinity distinguishes tin from other dentifrice antimicrobials: triclosan and zinc do not demonstrate LPS binding.
There is also direct antibacterial action. Stannous is bacteriostatic and bactericidal across a broad spectrum, interferes with adherence and colonization, and penetrates the cell wall to disrupt metabolism. Imaging work describes stannous fluoride forming aggregates between the outer and inner membranes of Porphyromonas gingivalis and Prevotella pallens, leading to membrane rupture.3 P. gingivalis is a keystone organism in periodontal disease, so the target selection is not incidental.
Worth connecting to the ecological argument made in how cavities form. Broad antibacterial approaches to caries have performed poorly because caries reflects an ecological shift in a resident community rather than infection by an outsider. Gingivitis is a different problem: it is an inflammatory response to biofilm accumulation, and reducing that accumulation or the host's reaction to it addresses the mechanism directly. The same intervention can be poorly targeted for one disease and well targeted for the other.
What the trials show
A meta-analysis of 18 randomized controlled gingivitis studies in 2,890 subjects reported a mean reduction of 51 percent in bleeding sites for stannous fluoride dentifrice against a negative control, over periods of three months or less.1 Individual trials are consistent with this: a 24-week randomized trial of 0.454% stannous fluoride reported substantial reductions in bleeding sites and gingival swelling, and a three-week study reported lower gingival bleeding, less inflammation and reduced plaque in adults with mild to moderate gingivitis.4
By the standards of dentifrice research this is a large and consistent effect, and it is considerably better evidenced than most claims made for toothpaste ingredients. Two qualifications belong with it. Bleeding on probing is a surrogate outcome, not tooth retention. And this literature is overwhelmingly manufacturer-funded, which is typical for the field and a reason for measured reading rather than dismissal, the same standard we apply to hydroxyapatite.
What the FDA position actually is
US stannous fluoride dentifrices are labeled with the purpose "anticavity, antigingivitis, antisensitivity" and carry claims including "helps prevent gingivitis" and "helps interfere with the harmful effects of plaque associated with gingivitis".5 Those claims are permitted, which is a meaningful fact and more than most oral care actives can say.
The regulatory structure beneath them is less settled than "FDA approved" suggests. The antigingivitis and antiplaque monograph, 21 CFR Part 356, was published as a proposed rule in May 2003 and has never been finalized.6 It remains a tentative monograph. Products marketed under it are lawful, but the rulemaking behind the category has sat unfinished for over twenty years.
A detail in that proposal is worth surfacing, because it is more informative than the label. The subcommittee recommended an antigingivitis statement of identity for stannous fluoride specifically because the data submitted to support effectiveness in reducing plaque were judged inconclusive. The careful wording on the tube, which talks about the effects of plaque associated with gingivitis rather than about removing plaque, is a direct artefact of that finding.
The trade-offs, which are the same chemistry
Sensitivity, as a benefit. In the presence of saliva, Sn(II) oxidizes to Sn(IV) and hydrolyzes to insoluble hydroxides, oxides, phosphates and fluorophosphates. These precipitate onto exposed dentin and into patent dentinal tubules, occluding them.1 That is the same physical strategy hydroxyapatite uses for sensitivity, arrived at by different chemistry.
Staining, as a cost. Oxidation also yields tin oxide, which is abrasive and readily roughens and stains the tooth surface. Reviews characterize this as a formulation problem addressed through stabilization rather than an inherent clinical inevitability, but the underlying chemistry is not removable, and extrinsic staining remains the best-known complaint about this ingredient class.
Contact reactions, as a rare cost. As set out in how fluoride works, the two largest case collections of oral soft tissue reactions attributed to fluoride dentifrice, published 67 years apart, both involved stannous formulations, and the one case with a positive patch test identified tin rather than fluoride as the allergen. The most parsimonious reading is that the tin accounts for both the therapeutic effect and the occasional idiosyncratic reaction. Those are not in tension; they are the same reactivity.
Where the evidence is strong and where it is not
Strong. That stannous fluoride reduces gingival bleeding and inflammation against control dentifrices. The LPS binding affinity and its distinction from zinc and triclosan. The tubule occlusion mechanism. The staining chemistry.
Weaker. Effect on plaque specifically, which the FDA subcommittee found inconclusive. Durability beyond three months, since most trials are short. Whether reduced bleeding translates into retained teeth over a lifetime, which no trial has measured.
Not claimed here. That stannous fluoride treats periodontitis. Gingivitis is reversible inflammation confined to soft tissue; periodontitis involves attachment and bone loss and requires professional treatment. Nothing in a tube addresses the second. And nothing on this page argues against using stannous fluoride: for someone with bleeding gums it is among the better-supported options available without a prescription. We make a fluoride-free toothpaste and do not compete on this indication.
References
- Stannous Fluoride in Toothpastes: A Review of Its Clinical Effects and Likely Mechanisms of Action. 2025. PMC11942899.
- Interactions and effects of a stannous-containing sodium fluoride dentifrice on oral pathogens and the oral microbiome. Frontiers in Microbiology. 2024;15:1327913. PMC10902866.
- Stannous fluoride forms aggregates between outer and inner membranes leading to membrane rupture of Porphyromonas gingivalis and Prevotella pallens. Frontiers in Oral Health. 2024;5:1427008. PMC11233731.
- A randomised clinical study investigating efficacy of a stannous fluoride toothpaste in improving gingival health after 3 weeks' use. PMC8436562.
- Crest Pro-Health Advanced Gum Protection, stannous fluoride 0.454%. OTC drug label, DailyMed, National Library of Medicine. DailyMed.
- Food and Drug Administration. Oral Health Care Drug Products for Over-the-Counter Human Use; Antigingivitis/Antiplaque Drug Products; Establishment of a Monograph. Proposed rule, 21 CFR Part 356. Federal Register, 29 May 2003. Federal Register.
This article is educational and describes published research and public regulatory documents. It is not medical or dental advice, not a diagnosis, and not a claim about any named product. We make a fluoride-free toothpaste and do not compete on this indication. Bleeding gums that do not settle are a reason to see a dentist, not to change toothpaste and wait.
Keep reading
Athena Naturals
Seven ingredients. Fluoride-free, no water, no preservatives, no surfactants. Made in small batches in Seattle.